Given that clinical trials targeting the accumulation of Aβ and hyperphosphorylated tau in the brain have nearly all ended in failure, deciphering the role of TREM2 in microglia will advance our understanding and provide novel therapeutic strategies for the treatment of AD and other neurodegenerative diseases. The gene discussed is MAPT; the disease is neurodegenerative disease.